'김갑성' 기자의 전체기사
-
Orange Biomed Lands on Fortune Korea's Top 40 with Porta…
SEATTLE, Aug. 22, 2025 -- Orange Biomed, developer of the world's first pocket-sized A1C testing device, is receiving international recognition for its breakthrough microfluidic technology designed to enhance accessibility and accuracy in chronic disease management. The company has been selected for inclusion in Fortune Korea's "Top 40 Emerging South Korean Healthcare Innovations", highlighting its growing momentum in the U.S. healthcare market. The company's flagship product, the OBM rapid A1C, is the first portable device to measure glycated hemoglobin (A1C) using m
- 김갑성 기자
- 2025-08-22 00:00
-
Doceree launches Premium Programmatic adding more con…
With Premium Programmatic, pharma marketers can now engage physicians across 2,000+ integrated specialist medical platforms delivering clinically aligned content at scale with unmatched precision and exclusive formats. SHORT HILLS, N.J., Aug. 21, 2025 -- Doceree, the only AI-powered operating system for healthcare marketing, today announced the launch of Premium Programmatic—a significant step forward in HCP programmatic advertising. The platform redefines how life sciences brands can activate the reading layer of the HCP journey—a critical point where physicians consume c
- 김갑성 기자
- 2025-08-21 21:32
-
ZEISS announces CE mark for CIRRUS PathFinder AI tool with auto…
Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care. JENA, Germany, Aug. 21, 2025 -- ZEISS Medical Technology today announced CE mark approval for CIRRUS® PathFinder™, an innovative clinical support tool with artificial intelligence (AI) fully integrated to enable more confident decision-making and accelerate a clinician's workflow with OCT interpretation assistance. ZEISS CIRRUS PathFinder1 uses proprietary deep learning algorithms to automatically identify abnorm
- 김갑성 기자
- 2025-08-21 20:00
-
SK bioscience Discusses Further Collaboration with the Ga…
Company holds a dedicated meeting with Gates Foundation executives during Bill Gates' visit to Korea. Both reviews expanded cooperation, including next-generation preventive medicines. SEONGNAM, South Korea, Aug. 21, 2025 -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company held an exclusive meeting with the Gates Foundation in line with the visit of Bill Gates, Founder and Chair of the Foundation, to Korea to discuss ways to advance global health collaboration.&nbs
- 김갑성 기자
- 2025-08-21 20:00
-
BioDlink's Bevacizumab Approved for Market Launch in Indon…
Bevacizumab Injection officially approved by Indonesia's National Agency of Drug and Food Control (BPOM), following Nigeria, Pakistan, and Colombia – accelerating global commercialization Approval in ASEAN's largest pharma market strengthens BioDlink's position as a global supplier of antibody/XDC therapies via international GMP standards and commercial capabilities SUZHOU, China, Aug. 21, 2025 -- BioDlink announced that its Bevacizumab Injection has obtained marketing authorization from Indonesia's National Agency of Drug and Food Control (BPOM). This mark
- 김갑성 기자
- 2025-08-21 20:00
-
FDA clearance of Salix® Coronary Plaque module
[ 메디채널 김갑성 기자 ] Significantly expands U.S. commercial opportunity with ability to charge fees per scan assessed Investor Webinar - 11.30am AEST (9.30am AWST) on 22 August 2025 PERTH, Australia, Aug. 21, 2025 -- Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration (the FDA) for Artrya's proprietary, Salix&r
- 김갑성 기자
- 2025-08-21 19:43
-
Brii Biosciences Provides Corporate Updates and Reports 20…
Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic soralimixin Strong Cash Position to Pursue New Discovery Opportunities and Partnership Strategy Conference Calls Scheduled: English Session: August 21 at 9:00 p.m. HKT / 9:00 a.m. ET Chinese Session: August 22 at 9:00 a.m. HKT / August 21 at 9:00 p.m. ET DURHAM, N.C., and BEIJING, Aug. 21, 2025 -- Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK),
- 김갑성 기자
- 2025-08-21 18:02
-
SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH…
[ 메디채널 김갑성 기자 ] Now in its fourth year, the programme continues to empower biotech startups through ecosystem support and collaboration to advance science that serves patients. SINGAPORE, Aug. 21, 2025 -- Singzyme, a Singapore-based biotech startup pioneering next-generation bioconjugation solutions, has been named the winner of the 2025 Golden Ticket Programme in Singapore. The award is part of a joint programme by Amgen, a U.S.-based leader in biologic medicines and NSG BioLabs, Singapore's leading provider of biotechnology co-working laboratories and offices. Now in
- 김갑성 기자
- 2025-08-21 17:38
-
GC Biopharma's Study on Hunterase Lysosomal Delivery Mec…
YONGIN, South Korea, Aug. 21, 2025 -- GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that it has revealed the delivery mechanism of Hunterase (idursulfase beta), a recombinant enzyme replacement therapy for Hunter syndrome (MPS II). The research findings, detailing the role of N-glycosylation in lysosomal targeting, have been published in the International Journal of Biological Macromolecules, a prestigious SCIE-indexed journal. Hunter syndrome (MPS II) is a rare genetic disorder caused by mutations in the iduronate-2-s
- 김갑성 기자
- 2025-08-21 13:00
-
Debut of new form of health supplement product! WCC biomed…
TAIPEI, Aug. 21, 2025 -- WCC Biomedical, a leader in novel drug delivery systems, will attend the upcoming NACDS Total Store Expo (TSE), where it will spotlight its proprietary WINMAP™ microarray patch (MAP) technology and launch two new products. To explore WINMAP™ technology for vaccines and pharmaceuticals, join WCC at the Total Store Expo on August 23–25 in San Diego, CA: Booth # 900 Following a successful debut at BIO Asia in Taiwan (July 23–27), WCC will offer demonstrations of its new products at TSE, allowing attendees to witness the benefits of microneedle-based
- 김갑성 기자
- 2025-08-21 09:23
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-22_WED
- Doing the Good Work: SM underscores practical sustainability at industry forum 18:08
- Cambrex Unveils $120 Million Investment to Expand API Manufacturing and Strengthen U.S. Drug Supply Resilience 18:00
- HUYA Inc. to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025 18:00
- 캠브렉스, API 제조 시설 확충과 미국 의약품 공급 회복력 강화 차원에서 1억 2000만 달러 투자 18:00
- ドバイは中東、アフリカ、南アジアを代表する世界金融センターとしての地位を向上 17:59
- 2025년 쇼상 시상식, 과학과 혁신의 22년 전통을 이어가다 17:54
- 2025年ショー賞（The Shaw Prize）授賞式：科学とイノベーションにおける22年の伝統を継承 17:53
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 22일 19시 40분